Duchenne Muscular Dystrophy Investigator-Initiated Research Award

The summary for the Duchenne Muscular Dystrophy Investigator-Initiated Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
Duchenne Muscular Dystrophy Investigator-Initiated Research Award: The DMDRP Investigator-Initiated Research Award (IIRA) supports translational research that will accelerate the movement of promising ideas in Duchenne research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations with the specific goal of developing new therapies. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information between basic and clinical science. Within this continuum, the IIRA supports later stage translational research projects, including early-phase, proof-of-principle clinical trials and correlative studies to better inform the development of drugs, devices, and other interventions. Research projects may also include preclinical studies utilizing animal models, human subjects, or human anatomical substances. Studies proposed under this award should not include: • Target discovery • Drug screening • Mechanism of action studies Biomarker Studies For projects addressing “discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers,” a biological marker, or biomarker, is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention.1 For the purpose of this award, biomarker qualification is defined as the evidentiary fit-for-purpose process of correlating a biomarker with the effects of an agent on biological processes and clinical endpoints.2 Alternatively, biomarker validation refers to the process of ensuring that a biomarker or technology (e.g., imaging) will be accurately and reliably measured through the performance characteristics of a biomarker assay.3 The DMDRP encourages the study of biomarkers that can be detected through minimally invasive procedures (e.g., blood, urine, tissue, imaging). Examples of biomarkers may include signatures of genetic or epigenetic changes, specifically expressed genes, proteins, or metabolites, and molecular, physiological, and/or imaging entities, among others.Candidate Biomarker(s) and Evaluation: Applications proposing biomarker qualification and/or validation studies should include a clear description of the candidate biomarker(s) to be studied. Applications must include relevant preliminary data from pilot testing that demonstrate the suitability of the biomarker(s) for further testing toward clinical application. Sufficient detail must be provided to demonstrate how the biomarker(s) will be qualified or validated, including the approaches that will be applied to establish feasibility, reliability, and reproducibility, and the criteria that will provide the evidence for evaluating the biomarkers. These criteria may include, but are not limited to: • Improved performance relative to current, clinically accepted biomarkers • Biological association of the biomarker(s) with Duchenne (e.g., muscle damage/fibrosis, cardiomyopathy, etc.) • Strength of association of changes in biomarker levels with pathological/clinical outcomes • Availability of a robust analytical assay to reliably and reproducibly assess the validity of the biomarker’s association with Duchenne or clinical outcomes • Evidence that a biomarker is a reliable indicator of target engagement, to support the decision-making process in clinical trials In addition, applications must be consistent with current U.S. Food and Drug Administration (FDA) guidance for biomarker qualification. Useful information can be found online at the following: FDA Biomarker Qualification Process: • http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm • http://www.c-path.org/pdf/FDADraftDDTools.pdf FDA Office of In Vitro Diagnostics and Radiological Health: • http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHOffices/ucm115904.htm All applications must include preliminary data that are relevant to Duchenne and the proposed project. Clinical trials are supported by this award mechanism and, if proposed, require the submission of Attachment 11, Human Subject Recruitment and Safety Procedures. The FY16 DMDRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and biotechnology/pharmaceutical industry scientists. Collaborations that bring new perspectives from other disciplines, or bring new investigators into the Duchenne field, are also strongly encouraged. Optional Nested Resident or Medical Student Traineeship: The IIRA mechanism allows for the inclusion of a Nested Resident or Medical Student Traineeship, which would allow the applicant to request additional funds as described in Section I.E., Funding. The Government reserves the right to fund an application at a lower funding level if it does not meet the eligibility criteria or intent of the optional feature. The intent of the Nested Resident or Medical Student Traineeship is to provide mentored research opportunities in Duchenne. It is expected that the training will provide a valuable opportunity to develop the experience necessary to advance the trainee’s research career in Duchenne. Only one traineeship may be requested per application. Plans for training and mentorship must be well developed and clearly described by the PI in the Statement of Traineeship.
Federal Grant Title: Duchenne Muscular Dystrophy Investigator-Initiated Research Award
Federal Agency Name: Dept of the Army USAMRAA
Grant Categories: Science and Technology
Type of Opportunity: Discretionary
Funding Opportunity Number: W81XWH-16-DMDRP-IIRA
Type of Funding: Cooperative Agreement, Grant
CFDA Numbers: 322755
CFDA Descriptions: Military Medical Research and Development
Current Application Deadline: Oct 19, 2016
Original Application Deadline: Oct 19, 2016
Posted Date: May 23, 2016
Creation Date: May 23, 2016
Archive Date: Nov 18, 2016
Total Program Funding: $1,920,000
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards: 2
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Grant Announcement Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
CDMRP Help Desk

Dept. of the Army -- USAMRAA 301-619-7144
More Grants from the Dept of the Army USAMRAA
DoD Accelerating Innovation in Military Medicine Research Award
DoD Psychological Health and Traumatic Brain Injury Peer Support Program Translational Res...
DoD Kidney Cancer, Idea Development Award
DoD Kidney Cancer, Consortium Development Award
DoD Kidney Cancer, Translational Research Partnership Award

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2017 FederalGrants.com